Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hyperlipidemias Age: Adult Condition: Homozygous familial hypercholesterolemia (HoFH), primary dysbetalipoproteinemia, hypertriglyceridemia, primary hyperlipidemia, or heterozygous familial hypercholesterolemia (HeFH) |
Dose: Tablet – 10 or 20 mg Frequency: once daily Note: Dosage range is 10 mg to 80 mg once daily. |
|
Indication: Hyperlipidemias Age: Adult Condition: Patients requiring LDL-C reduction greater than 45% |
Dose: Tablet – 40 mg Frequency: once daily Note: Dosage range is 10 mg to 80 mg once daily. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Heterozygous Familial Hypercholesterolemia Age: less than 10 years |
Dose: Oral – Not established Note: Safety and efficacy not established |
|
Indication: Heterozygous Familial Hypercholesterolemia Age: greater than 10 years |
Dose: Oral – 10 mg Frequency: once daily Note: initially; titrate at 4-week intervals; not to exceed 20 mg by mouth once daily |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Tablet – No dosage adjustment Note: Renal impairment does not affect atorvastatin plasma concentrations. Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. |
Administration
- Take with or without food
- Take in evening
Side Effect
- Diarrhea (5-14%)
- Nasopharyngitis (4-13%)
- Arthralgia (4-12%)
- Insomnia (1-5%)
- Urinary Tract Infection (UTI) (4-8%)
- Nausea (4-7%)
- Dyspepsia (3-6%)
- Increased transaminases (2-3%)
- Muscle spasms (2-5%)
- Musculoskeletal pain (2-5%)
- Myalgia (3-8%)
- Limb pain (3-8%)
- Pharyngolaryngeal pain (1-4%)
- Angina
- Syncope
- Dyspnea
- Myopathy
- Anaphylaxis
- Stevens-Johnson syndrome
- Myositis
- Thrombocytopenia
- Rhabdomyolysis with acute renal failure
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4 potent inhibitors, Fenofibrate, Colchicines, Lopinavir/ritonavir
|
May increase risk of myopathy and rhabdomyolysis
|
|
CYP3A4 inducers
|
May decrease plasma concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Active Liver Disease, Unexplained Persistent Elevations of Serum Transaminase
|
Can worsen liver function
|
|
Porphyria
|
Can trigger acute attacks
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep in a dry place away from light and heat. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.